Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials

Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer treatment. Peripheral T cell response dynamics have demonstrated incons...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1090533
Main Authors McCarthy, Patrick M, Valdera, Franklin A, Smolinsky, Todd R, Adams, Alexandra M, O'Shea, Anne E, Thomas, Katryna K, Van Decar, Spencer, Carpenter, Elizabeth L, Tiwari, Ankur, Myers, John W, Hale, Diane F, Vreeland, Timothy J, Peoples, George E, Stojadinovic, Alex, Clifton, Guy T
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 07.03.2023
Subjects
cancer vaccine
Cancer Vaccines - therapeutic use
checkpoint inhibition
endpoint
Humans
Immunology
Immunotherapy
Lymphocytes, Tumor-Infiltrating
Neoplasms - pathology
Neoplasms - therapy
tumor infiltrating lymphocyte (TIL)
Tumor Microenvironment
vaccination
endpoint
tumor infiltrating lymphocyte (TIL)
cancer vaccine
checkpoint inhibition
immunotherapy
vaccination
Online AccessGet full text

Cover

More Information
Summary:Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer treatment. Peripheral T cell response dynamics have demonstrated inconsistency in assessing the efficacy of cancer vaccination. Tumor infiltrating lymphocytes (TILs), reflect the local tumor microenvironment and may prove a superior endpoint in cancer vaccination trials. Cancer vaccines may also promote success in combination immunotherapy treatment of weakly immunogenic tumors. This review explores the impact of TILs as an endpoint for cancer vaccination in multiple malignancies, summarizes the current literature regarding TILs analysis, and discusses the challenges of providing validity and a standardized implementation of this approach.
Bibliography:content type line 23
SourceType-Scholarly Journals-1
Reviewed by: Norberto Walter Zwirner, National Scientific and Technical Research Council (CONICET), Argentina; Roberta Castriconi, Università di Genova, Italy
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
Edited by: Mrinmoy Sanyal, Stanford University, United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1090533